Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab

Wolford, JE; Bai, JR; Minion, LE; Keller, R; Eskander, RN; Chan, JK

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索